Now, it’s worth noting Stock Advisor’s total average return is 1,058% — a market-crushing outperformance compared to 189 % ...

In a study with people with Type 2 diabetes and cardiovascular disease, the drug Ozempic was shown to reduce the risk of ...

People with new-onset type 1 diabetes can achieve similar improvements in C-peptide levels with a 0.5 mg/kg antithymocyte ...

In the SURPASS-CVOT trial, tirzepatide was similar to dulaglutide for prevention of cardiovascular death, heart attack and stroke at 4 years, researchers reported at the European Association for the ...

The Silvant Large Cap Growth SMA returned +18.62% (gross)/+17.74% (net) for the quarter, outperforming the Russell 1000 ...

Amazon, which has the largest presence outside the USA in Telangana, announced major decisions in the meeting. The global major would aggressively promote its SME sellers on the platform for exports.

The industry’s final months of 2025 could be action-packed as the FDA renders approval decisions on drugs that would be ...

With a market cap of $708 billion, Eli Lilly isn't far from becoming the first trillion-dollar healthcare company.

None of that happened. So if you're a long-term investor who's willing to take on some risk, Viking Therapeutics is a pharma ...

New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in ...

Lilly’s cardiovascular outcomes trial is the first to use an active comparator, finding noninferiority but not superiority of ...

Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, ...